[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644986":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":19,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":19,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":19,"overallStatus":68,"whyStopped":19,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Age-Stratified Conditioning Regimen","MDS patients without identical sibling donor or unrelated donor would receive haplo-HSCT. Participants will receive either reduced-toxicity Bu\u002FFlu\u002FCy\u002FATG conditioning regimen (for patients aged ≥55 years) or standard myeloablative modified Bu\u002FCy+ATG conditioning regimen (for patients aged \\\u003C55 years) followed by unified post-transplant immunosuppression and supportive care.",[12],"Drug: RTC conditioning regimen and Modified Bu\u002FCy conditioning regimen",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","RTC conditioning regimen and Modified Bu\u002FCy conditioning regimen","RTC preconditioning regimen consisted of cytarabine (2g\u002Fm2\u002Fday, days -10 to -9), busulfan (3.2 mg\u002Fkg\u002Fday on days -8 to -6), cyclophosphamide (1.0 g\u002Fm2\u002Fday, days -5 to -4), fludarabine (30 mg\u002Fm2\u002Fday, days -6 to -2), semustine (250 mg\u002Fm2, day-3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg\u002Fkg\u002Fd, days -5 to -2; Sanofi, France). Bu\u002FCy preconditioning regimen consisted of tandard institutional myeloablative busulfan + cyclophosphamide + rabbit ATG regimen per department routine dosing guidelines.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Xiao-Jun Huang","Peking University Institute of Hematology","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Yu Wang","CONTACT","8610-8832-6005","ywyw3172@sina.com",[32],{"facility":33,"status":19,"city":34,"state":19,"zip":19,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Peking University People's Hospital, Beijing Lu Daopei Hematology Hospital, Hebei Yanda Lu Daopei Hospital, Nanfang Hospital, Southern Medical University","Beijing","China","CN",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},[44],{"name":45,"role":28,"phone":29,"phoneExt":19,"email":46},"Xiaojun Huang","huangxiaojun@bjmu.edu.cn",{"type":24,"investigatorFullName":22,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"director","100644986","phase-2-age-stratified-conditioning-regimen-efficacy-for-mds-haplo-hsct-100644986",false,"NCT07677306","Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT","Prospective Cohort Study of Age-Stratified Busulfan-Based Conditioning Regimens in Adult Patients With Myelodysplastic Syndrome Receiving Haploidentical Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patients who had low- and intermediate-risk MDS without ISD nor URD receiving haploidentical hematopoietic stem cell transplantation\n\nExclusion Criteria:\n\n* Patients having ISD or URD; patients having high-risk MDS; patients with active infection; patients with poor compliance; patients with organ failure","ALL","18 Years","65 Years",{"count":60,"type":61},120,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This study plan aims to enroll adult patients diagnosed with myelodysplastic syndrome (MDS) who are scheduled to receive T-cell-replete haploidentical hematopoietic stem cell transplantation. After obtaining written informed consent, participants will receive either reduced-toxicity Bu\u002FFlu\u002FCy\u002FATG conditioning regimen (for patients aged ≥55 years) or standard myeloablative modified Bu\u002FCy+ATG conditioning regimen (for patients aged \\\u003C55 years) followed by unified post-transplant immunosuppression and supportive care. The objective is to prospectively characterize the 1-year transplant-related mortality and comprehensively evaluate hematopoietic engraftment, graft-versus-host disease, infection, relapse, survival outcomes and conditioning-related organ toxicity among all enrolled patients undergoing haploidentical transplantation.",[67],"Myelodysplastic Syndromes","NOT_YET_RECRUITING","2026-06-24",{"date":71,"type":72},"2026-06-30","ACTUAL",{"date":74,"type":61},"2026-07-15",{"date":76,"type":61},"2028-06-30",{"name":5,"class":6},1]